Abstract
We have carried out an in vitro study of the growth inhibitory capacity of the neurokinin-1 receptor antagonist L-733,060 at concentrations ranging from 5μM to 40μM against the human pancreas adenocarcinoma CAPAN-1 and PA-TU 8902 cell lines. We also studied the mitogenic action of substance P on both cancer cell lines. A Coulter counter was used to determine viable cell numbers, followed by application of the MTS colorimetric method to evaluate cell viability in these cytotoxicity assays. Nanomolar concentrations of substance P increased the growth of both cell lines and micromolar concentrations of L-733,060 inhibited the growth of the CAPAN-1 and PA-TU 8902 cell lines studied in a dose-dependent manner. The IC50 values were 20.02μM for CAPAN-1 and 18.11μM for PA-TU 8902. In order to demonstrate the presence of neurokinin- 1 receptors in these cancer cell lines, an immunoblot analysis was used. Four bands of 34, 46, 58 and 75 kDa were observed in both cell lines. These new findings suggest that the neurokinin-1 receptor is a new target and that the neurokinin-1 receptor antagonist L-733,060 could be a promising therapeutic drug for the treatment of human pancreas adenocarcinoma.
Keywords: Pancreas adenocarcinoma, CAPAN-1, PA-TU 8902, cell proliferation, NK-1 receptor antagonists, tachykinins
Letters in Drug Design & Discovery
Title: The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines
Volume: 3 Issue: 5
Author(s): Miguel Munoz, Marisa Rosso and Rafael Covenas
Affiliation:
Keywords: Pancreas adenocarcinoma, CAPAN-1, PA-TU 8902, cell proliferation, NK-1 receptor antagonists, tachykinins
Abstract: We have carried out an in vitro study of the growth inhibitory capacity of the neurokinin-1 receptor antagonist L-733,060 at concentrations ranging from 5μM to 40μM against the human pancreas adenocarcinoma CAPAN-1 and PA-TU 8902 cell lines. We also studied the mitogenic action of substance P on both cancer cell lines. A Coulter counter was used to determine viable cell numbers, followed by application of the MTS colorimetric method to evaluate cell viability in these cytotoxicity assays. Nanomolar concentrations of substance P increased the growth of both cell lines and micromolar concentrations of L-733,060 inhibited the growth of the CAPAN-1 and PA-TU 8902 cell lines studied in a dose-dependent manner. The IC50 values were 20.02μM for CAPAN-1 and 18.11μM for PA-TU 8902. In order to demonstrate the presence of neurokinin- 1 receptors in these cancer cell lines, an immunoblot analysis was used. Four bands of 34, 46, 58 and 75 kDa were observed in both cell lines. These new findings suggest that the neurokinin-1 receptor is a new target and that the neurokinin-1 receptor antagonist L-733,060 could be a promising therapeutic drug for the treatment of human pancreas adenocarcinoma.
Export Options
About this article
Cite this article as:
Munoz Miguel, Rosso Marisa and Covenas Rafael, The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines, Letters in Drug Design & Discovery 2006; 3 (5) . https://dx.doi.org/10.2174/157018006777574168
DOI https://dx.doi.org/10.2174/157018006777574168 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Graphical Abstracts
Letters in Drug Design & Discovery Graphene and Graphene Oxide as a Docking Station for Modern Drug Delivery System
Current Drug Delivery Glial Cell: A Potential Target for Cellular and Drug Based Therapy in Various CNS Diseases
Current Pharmaceutical Design Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases
Current Pharmaceutical Biotechnology The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Current Molecular Medicine Design and Synthesis of Tetrahydroisoquinoline Derivatives as Anti-Angiogenesis and Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry AGE-RAGE System and Carcinogenesis
Current Pharmaceutical Design T Cell Suicide Gene Therapy to Aid Haematopoietic Stem Cell Transplantation
Current Gene Therapy Anti-tumor Therapeutic Molecules that Target the Programmed Cell Death Machinery
Mini-Reviews in Medicinal Chemistry A New Approach for Cancer Immunotherapy Based on the Cancer Stem Cell Antigens Properties
Current Molecular Medicine Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance
Current Cancer Therapy Reviews Role of Cannabinoids and Endocannabinoids in Cerebral Ischemia
Current Pharmaceutical Design Cyclophilin A as a Target of Cisplatin Chemosensitizers
Current Cancer Drug Targets The Potential Therapeutic Value of Renin-Angiotensin System Inhibitors in the Treatment of Colorectal Cancer
Current Pharmaceutical Design Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry Isolation, Purification and Characterization of a Novel Steroidal Saponin Cholestanol Glucoside from Lasiodiplodia theobromae that Induces Apoptosis in A549 Cells
Anti-Cancer Agents in Medicinal Chemistry Serum Biochemical Markers of Brain Injury
Mini-Reviews in Medicinal Chemistry HSP60 as a Drug Target
Current Pharmaceutical Design Computational Analysis of miRNA and their Gene Targets Significantly Involved in Colorectal Cancer Progression
MicroRNA Inhibitor at the Gates, Inhibitor in the Chamber: Allosteric and Competitive Inhibitors of the Proteasome as Prospective Drugs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents